Medicare to pursue ‘robust’ patient, clinician discussions in future drug price negotiations
Medicare will pursue “more robust discussions” with patients and clinicians as it begins its second round of drug price negotiations, the program’s director said Wednesday in Milwaukee.
To access this content, you must purchase a Premium membership, or log in if you are a member.
